Monopar Therapeutics Inc (MNPR) is a clinical-stage biopharmaceutical company regarded for its relentless and targeted focus on developing therapies for the treatment of cancer and other severe diseases with high unmet medical needs. Born out of a passionate commitment to enhance healthcare and improve patients' lives, Monopar Therapeutics brings unique value and high potential for growth in the pharmaceutical industry.
Monopar Therapeutics was founded through an alignment of vision among its three founders—Andrew Mazar, Chandler Robinson, and Christopher M. Starr—who believe in creating therapeutics that can significantly improve the health of people. The company is driven by a team of experienced professionals who combine their scientific, clinical, financial and business acumen to propel Monopar's therapeutic products from scientific conception to commercial reality.
The company’s lead product candidates from its robust pipeline include Validive (clonidine MBT), a Phase 2-ready candidate for the prevention and treatment of severe oral mucositis (SOM) caused by cancer radiation and chemotherapy; CamSA (a small molecule), a potential first-in-class drug candidate for the treatment of severe COVID-19 and other hyperinflammatory conditions; and MNPR-101, a preclinical monoclonal antibody for the treatment of various forms of cancer.
The company has partnered with leading academic institutions, pharmaceutical companies, and data-driven organizations to bring innovative medicines to patients in need, and it continues to seek partnerships and collaborations to expand its product pipeline. Monopar Therapeutics is listed on the NASDAQ Stock Market and has its corporate office in Wilmette, Illinois.
Monopar Therapeutics’ dedication to nurturing innovative scientific concept to a potential real-world solution is a testament to its strong commitment to combating devastating diseases. The company prides itself on fostering an environment that promotes scientific excellence, rigorous research, and a patient-centric approach. Its robust pipeline of potential drugs and therapies, matched with its relentless pursuit of enhancing healthcare, positions it at a unique point in the biotechnology landscape.
While Monopar Therapeutics collaborates with others, they are unwavering in their mission to transform lives by advancing medicines with the potential to significantly improve outcomes for patients with cancers and severe diseases worldwide. Monopar Therapeutics' reputation for excellent research and the potential of their work is shaping the future of biotechnological advancement and disease management.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Monopar Therapeutics Inc. announced that two abstracts related to its investigational Wilson disease therapy, ALXN1840, will be presented at The Liver Meeting® 2026. The presentations will cover baseline characteristics from the Phase 3 FoCus trial, assessing disease burden in Wilson disease patients, and molybdenum balance and safety data for ALXN1840. These findings support the drug's safety profile and its potential as an innovative treatment for the rare genetic disorder.
Monopar Therapeutics Inc. (NASDAQ: MNPR) is exhibiting weak near and mid-term sentiment, despite a potentially strong long-term outlook. AI models have generated three trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, with an exceptional 112.0:1 risk-reward setup targeting a 32.3% gain against 0.3% risk.
This article analyzes Monopar Therapeutics Inc. (NASDAQ: MNPR), noting weak near- and mid-term sentiment despite a long-term positive outlook. AI models have generated three trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights an exceptional 113.1:1 risk-reward setup targeting a 32.6% gain against 0.3% risk.